UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Update on taxane development: new analogs and new formulations

Drug design, development and therapy, 2012, Vol.6 (default), p.371-384

2012

Volltextzugriff (PDF)

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

Journal of clinical oncology, 2003-03, Vol.21 (6), p.976-983

2003

Volltextzugriff (PDF)

Body mass and stage of breast cancer at diagnosis

International journal of cancer, 2002-03, Vol.98 (2), p.279-283

2002

Volltextzugriff (PDF)

Abstract P1-12-01: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-12-01

2017

Volltextzugriff (PDF)

Social support as a buffer to the psychological impact of stressful life events in women with breast cancer

Cancer, 2001-01, Vol.91 (2), p.443-454

2001

Volltextzugriff (PDF)

Abstract P5-15-08: Clinical factors that contribute to choice of mastectomy in patients eligible for breast conservation therapy

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P5-P5-15-08

2013

Volltextzugriff (PDF)

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

Anti-cancer drugs, 2003-03, Vol.14 (3), p.239-246

2003

Volltextzugriff (PDF)

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

JNCI : Journal of the National Cancer Institute, 1993-04, Vol.85 (8), p.611-621

1993

Volltextzugriff (PDF)

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

Journal of clinical oncology, 1995-09, Vol.13 (9), p.2174-2186

1995

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors

Journal of clinical oncology, 2000-09, Vol.18 (18), p.3288-3294

2000

Volltextzugriff (PDF)

A phase I study of paclitaxel, UFT, and leucovorin

Oncology (Williston Park, N.Y.), 2000-10, Vol.14 (10 Suppl 9), p.76

2000

Volltextzugriff (PDF)

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

Journal of clinical oncology, 1994-01, Vol.12 (1), p.166-175

1994

Volltextzugriff (PDF)

Phase I study of docetaxel and topotecan in patients with solid tumors

Cancer chemotherapy and pharmacology, 2000, Vol.46 (6), p.442-448

2000

Volltextzugriff (PDF)

Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women?

Journal of women's health & gender-based medicine, 2002-07, Vol.11 (6), p.527-536

2002

Volltextzugriff (PDF)

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(14)

Sprache

Englisch
(14)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Aged
(11)
Middle Aged
(11)
Oncology
(10)
Adult
(9)
Female
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Antineoplastic Agents
(6)
Chemotherapy
(6)
Infusions, Intravenous
(6)
Male
(6)
Breast Neoplasms - Pathology
(5)
Paclitaxel - Administration & Dosage
(5)
Pharmacology. Drug Treatments
(5)
Drug Administration Schedule
(4)
Neoplasms - Drug Therapy
(4)
Antineoplastic Agents - Adverse Effects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Update on taxane development: new analogs and new formulations

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

Body mass and stage of breast cancer at diagnosis

Abstract P1-12-01: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases

Social support as a buffer to the psychological impact of stressful life events in women with breast cancer

Abstract P5-15-08: Clinical factors that contribute to choice of mastectomy in patients eligible for breast conservation therapy

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors

A phase I study of paclitaxel, UFT, and leucovorin

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

Phase I study of docetaxel and topotecan in patients with solid tumors

Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women?

Suchergebnisse filtern